Last reviewed · How we verify
A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis
This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).
Details
| Lead sponsor | Genzyme, a Sanofi Company |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 12 |
| Start date | 2007-02 |
| Completion | 2007-07 |
Conditions
- Secondary Hyperparathyroidism
Interventions
- Hectorol (doxercalciferol injection)
- Zemplar (Paricalcitol injection)
Primary outcomes
- Pharmacokinetic Study — 44 hour interval
Countries
United States